CUAMC
ESPR

China Universal Asset Management Company’s Esperion Therapeutics ESPR Stock Holding History

China Universal Asset Management Company’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$116K Buy
42,424
+3,469
+9% +$11K 0.01% 395
2025
Q4 		$144K Buy
38,955
+3,614
+10% +$11.7K 0.01% 380
2025
Q3 		$93.7K Sell
35,341
-4,467
-11% -$8.64K 0.01% 391
2025
Q2 		$39.2K Buy
39,808
+286
+0.7% +$286 ﹤0.01% 432
2025
Q1 		$56.9K Sell
39,522
-2,257
-5% -$4.16K 0.01% 411
2024
Q4 		$91.9K Buy
+41,779
New +$97.5K 0.01% 403
2023
Q4 		– Sell
-2,748
Closed -$2.69K – 445
2023
Q3 		$2.69K Buy
2,748
+1,507
+121% +$2.18K ﹤0.01% 421
2023
Q2 		$1.73K Buy
1,241
+203
+20% +$283 ﹤0.01% 435
2023
Q1 		$1.65K Buy
1,038
+289
+39% +$1.49K ﹤0.01% 438
2022
Q4 		$4.67K Buy
749
+126
+20% +$901 ﹤0.01% 307
2022
Q3 		$4K Buy
+623
New +$4.28K ﹤0.01% 295

Other funds holding ESPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

China Universal Asset Management Company's ESPR Position: Q1 2026 in Review

China Universal Asset Management Company increased its Esperion Therapeutics (ESPR) stake by 8.9% in Q1 2026, buying an estimated $11K and bringing the position to 42,424 shares worth $116K. The position accounts for 0.01% of the portfolio, ranked #395.

China Universal Asset Management Company first reported a position in ESPR in Q3 2022 and has held it in 11 quarters since. The position peaked at $144K in Q4 2025. 205 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

  • China Universal Asset Management Company held 42,424 shares of Esperion Therapeutics worth $116K as of Q1 2026.
  • China Universal Asset Management Company bought 3,469 Esperion Therapeutics shares in Q1 2026, an estimated $11K.
  • Esperion Therapeutics made up 0.01% of China Universal Asset Management Company's portfolio in Q1 2026, its #395 holding.
  • China Universal Asset Management Company first reported a position in Esperion Therapeutics in Q3 2022 and has held it in 11 quarters since.
  • China Universal Asset Management Company's Esperion Therapeutics position peaked at $144K in Q4 2025.
  • 205 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on China Universal Asset Management Company's 13F filing for Q1 2026, filed 28 Apr 2026.